Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$11.27 USD
+0.23 (2.08%)
Updated Aug 14, 2024 03:59 PM ET
After-Market: $11.05 -0.22 (-1.95%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Brokerage Reports
Dynavax Technologies Corporation [DVAX]
Reports for Purchase
Showing records 41 - 60 ( 124 total )
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
1Q21 Results; Strong CpG 1018 Adjuvant Sales Overshadow Heplisav-B YOY Sales Decline
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 Trial of Valneva''s COVID-19 Vaccine Candidate Adjuvanted With Dynavax''s CpG 1018 Initiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Solid Phase 1/2 Initial Results Reported for VLA2001 Vaccine Candidate Adjuvanted With CpG 1018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
First Participants Dosed in Phase 2/3 SPECTRA COVID-19 Vaccine Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Potential Universal Recommendation for Hepatitis B Vaccine and Multiple COVID-19 Vaccine Data Readouts in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
European Commission Approves Heplisav-B for Hepatitis B Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Tetanus and Pertussis Vaccine Phase 1 Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
A Plethora of Positive News for Dynavax''s COVID-19 Programs; Raising PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
First Patient Dosed With Medigen''s COVID-19 Vaccine Adjuvanted with CpG 1018 in Phase 2 Trial in Taiwan
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Strong Final Immunogenicity Data Posted for Patients Undergoing Hemodialysis Treated With Heplisav-B
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
First Participants Dosed in the Serum Institute of India''s Phase 1/2 Trial Evaluating its COVID-19 Vaccine With CpG 1018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Positive CHMP Opinion for Heplisav-B in Hepatitis B
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Strong Immune Responses From Clover''s COVID-19 Candidate With Dynavax''s CpG 1018 Adjuvant
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Another COVID-19 Vaccine Candidate Utilizing CpG 1018 Enters Phase 1/2 Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
3Q20 Results; Solid Heplisav-B Sales; CpG 1018 Supply Agreement Could Dramatically Increase Revenues; Raising PT by $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 1 Trial Evaluating Medigen''s COVID-19 Vaccine Combined With Dynavax''s CpG 1018 Adjuvant
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Clover''s COVID-19 Vaccine With CpG 1018 Continues to Move Forward in Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Dynavax and Valneva Announce Commercial Supply Agreement of CpG 1018 for Valneva''s COVID-19 Vaccine Candidate
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Preliminary Phase 1/2 Results of Sinovac''s COVID-19 Vaccine Candidate Released
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Dynavax Announces Grant of $3.4 Million From the Bill - Melinda Gates Foundation
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E